| | | 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于股份回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2025/4/29，由董事长唐咏群先生提议 | | --- | --- | | 回购方案实施期限 | 2025 年 5 月 20 日~2026 年 5 月 19 日 | | 预计回购金额 | 2,000万元~4,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 137.9995万股 | | 累计已回购股数占总股本比例 | 0.09% | | 累计已回购金额 | 1,500.85万元 | | 实际回购价格区间 | 9.56元/股~11.66元/股 | 截至 2026 年 02 月 28 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购股份 137.9995 万股，已累计回购股份占公司总股本的比例为 0 ...

行 业 及 产 业 医药生物 行 业 研 究 / 行 业 点 评 证 券 研 究 报 告 《本周申万医药生物指数下跌 0.8%，关注 基药目录发布——医药行业周报 （2026/02/09-2026/02/20）》 2026/02/23 《本周申万医药生物指数上涨 0.14%，关 注中药高质量发展方案——医药行业周报 （2026/02/02-2026/02/06）》 2026/02/09 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 陈田甜 A0230524080013 chentt@swsresearch.com 联系人 陈田甜 A0230524080013 chentt@swsresearch.com 2026 年 03 月 02 日 本 周 申 万 医 药 生 物 指 数 上 涨 0.5%，关注大宗原料药价格上涨 看好 —— 医药行业周报（2026/02/23-2026/02/27） 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 相关研究 ⚫ 市场表现：本周申万医药生物指数上涨 0.5%，同期 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 三、对公司的影响 新批准产品进一步丰富了公司国际化的产品管线，强化公司国际市场布局。若后续推进美国市场上市销 售，有望对公司经营业绩产生积极影响。 四、风险提示 公司高度重视药品研发，严格控制药品研发、生产、销售环节的质量和安全。但产品的生产和销售容易 受国家政策、市场环境等不确定因素的影响，有可能存在销售不达预期等情况。敬请广大投资者谨慎决 策，注意防范投资风险。 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）子公司香港健友实业有限公司（以下 简称"香港健友"）于近日收到美国食品药品监督管理局（以下简称"美国FDA"）签发的来法莫林注射 液，150 mg/15 mL，单剂量（NDA号：211673）生产场地转移批准信，批准在公司子公司健进制药有 限公司场地生产。现将相关情况公告如下： 一、药品的基本情况 二、药品其他相关情况 公司于近日收到美国FDA的通知，公司子公司香港健友向美国FDA申报的来法莫林注射液，150 mg/15 mL（NDA号：211673 ...

证券日报网讯 2月26日，健友股份发布公告称，公司子公司香港健友实业有限公司于近日收到美国食品 药品监督管理局（简称"美国FDA"）签发的来法莫林注射液，150mg/15mL，单剂量（NDA号： 211673）生产场地转移批准信，批准在公司子公司健进制药有限公司场地生产。 （编辑 任世碧） ...

| 证券代码：603707 | 证券简称：健友股份 公告编号：2026-007 | | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | 南京健友生化制药股份有限公司 关于子公司获得美国 FDA 来法莫林注射液 药品生产场地转移注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）子公 司香港健友实业有限公司（以下简称"香港健友"）于近日收到美国食品药品监 督管理局（以下简称"美国 FDA"）签发的来法莫林注射液，150 mg/15 mL， 单剂量（NDA 号：211673）生产场地转移批准信，批准在公司子公司健进制药 有限公司场地生产。现将相关情况公告如下： 一、药品的基本情况 二、药品其他相关情况 新批准产品进一步丰富了公司国际化的产品管线，强化公司国际市场布局。 若后续推进美国市场上市销售，有望对公司经营业绩产生积极影响。 四、风险提示 公司高度重视药品研发，严格控制药品研发、生产、销售环节的质量和安全。 但产品的 ...

健友股份公告，子公司香港健友向美国FDA申报的来法莫林注射液，150mg/15mL（NDA号：211673） 生产场地转移至健进制药有限公司的申请已获得批准。来法莫林注射液作为创新药，于2019年8月19日 获得美国FDA批准上市，商品名为XENLETA。经查询，美国目前暂无仿制药获批上市。 ...

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [28][37]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 1.91% from January 23 to February 5, 2026, which is approximately 0.74 percentage points lower than the index [12]. - Most sub-sectors within the industry recorded negative returns during the same period, with offline pharmacies and vaccine sectors showing the best performance, increasing by 3.01% and 0.12% respectively, while other sectors like biological products and chemical preparations saw declines of 3.28% and 3.27% [13]. - Approximately 34% of stocks in the industry recorded positive returns, while 66% experienced negative returns during the reporting period [14]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 51.00 times as of February 5, 2026, indicating a decrease in industry valuation [18]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 1.91% from January 23 to February 5, 2026 [12]. - Most sub-sectors recorded negative returns, with offline pharmacies and vaccines performing relatively well [13]. - About 34% of stocks in the industry had positive returns, with significant variations in individual stock performance [14]. - The industry valuation has decreased, with a PE ratio of approximately 51.00 times [18]. 2. Industry News - The 11th batch of national procurement results is set to be implemented in February, with notifications already released by 17 provinces [26]. - The National Medical Insurance Administration has issued a notice to accelerate the cultivation and opening of application scenarios in the medical insurance field [25]. 3. Company Announcements - Jianyou Co., Ltd. announced that its subsidiary received FDA approval for its product, sodium selenite injection [27]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector as part of the 14th Five-Year Plan, with ongoing policy support [28]. - Recommended sectors for investment include medical devices, pharmaceutical commerce, aesthetic medicine, scientific services, hospital and diagnostic services, traditional Chinese medicine, innovative drugs, biological products, and CXO services [29].

Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has released a public list of green factories and green industrial parks for the year 2025, highlighting the importance of sustainable development in the manufacturing sector [2]. Group 1: Green Factories and Industrial Parks - The list includes newly cultivated green factories and industrial parks, as well as those undergoing dynamic management adjustments, which were recommended by provincial industrial and information departments and reviewed by experts [4]. - Notable companies included in the list are Beijing Haibo Sichuang Technology Co., Ltd., Envision Energy Technology (Jiangsu) Co., Ltd., and Honeycomb Energy Technology Co., Ltd. [3][4]. Group 2: Contact Information and Public Notice - The public notice period for the list is from February 5, 2026, to February 19, 2026, during which any objections can be submitted to the MIIT [5]. - The contact unit for inquiries is the Energy Conservation and Comprehensive Utilization Department of the MIIT, with a provided contact number for further communication [5].

Summary of Conference Call Notes Industry Overview Real Estate Market - New home sales in core cities are still experiencing negative growth, while the second-hand housing market saw significant increases in transaction volume year-on-year and month-on-month due to early demand for school district properties and supply lagging behind, leading to a rise in both volume and price [1][3] - Anticipation for continued market heat in March, with April's performance dependent on policy support. A potential policy package similar to that of September 24, 2024, could signal a fundamental turning point in core urban areas by the end of 2026 [1][4] - Real estate stocks typically lead the fundamentals by 2-3 quarters, suggesting Q2 may be a good time to increase allocations [4] Construction and Building Materials - The construction and building materials sector is currently in a subdued state, with many projects halted due to the approaching Spring Festival and downstream demand not yet released [6] - Cement prices are continuously declining, with a recent drop of 0.8%. Glass demand is shrinking, and prices remain stable, while manufacturers of consumer building materials are promoting price increases [6][10] - The sector is at historical low levels, presenting opportunities for capital rebalancing [7] Express Delivery Industry - Domestic express delivery business saw a high growth rate of approximately 20% in January, influenced by the timing of the Spring Festival. There is a noticeable divergence in growth rates among leading companies [8] - Jitu Express benefits from the rapid growth of TikTok in Southeast Asia and Latin America, predicting high growth in shipment volume for Q1 due to promotional activities [8] Oil Transportation Industry - Since August 2025, oil transportation rates have significantly increased due to improved supply-demand dynamics and tightening sanctions. The BDTI index has nearly doubled year-on-year as of February 2, 2026 [9][11] - The mid-term outlook suggests continued upward pressure on rates due to geopolitical events and sanctions, providing substantial earnings elasticity for companies in this sector [11] Chemical Logistics - Chemical prices have gradually recovered since late 2025, although they remain at five-year lows. The industry is expected to experience a recovery in trade activity and inventory digestion, leading to improved logistics conditions [12] Civil Aviation - Domestic civil aviation demand is robust, with January passenger volume increasing nearly 9% year-on-year. The Spring Festival period is expected to exceed historical peak levels for passenger volume [13][14] - The average ticket price has increased by 2.4% year-on-year, with a notable rise in pre-sale ticket prices expected in the coming weeks [13][14] Road Transportation - High-speed road freight throughput reached 241 million vehicles in January, marking a year-on-year increase of 22.8%. Predictions indicate significant population movement during the Spring Festival, with a projected increase in passenger volume [15] Key Recommendations - For real estate, focus on companies like China Merchants Shekou, New Town Holdings (A-shares), and China Resources Land (H-shares) [5] - In the construction sector, consider leading firms such as Yuhong, Sankeshu, Tubao, and China Jushi [7] - In the express delivery sector, maintain a watch on leading domestic companies and Jitu Express for overseas delivery [16] - For oil transportation, prioritize companies like China Merchants Energy and COSCO Shipping Energy [11] - In the chemical logistics space, look at companies like Meikewei, Xingtong Co., and Hongtan Wisdom for potential performance rebounds [12] - In civil aviation, monitor the evolving pricing strategies of airlines as they shift towards price control [14]

Group 1 - Sileck's subsidiary received a project designation letter from a South Korean battery customer, expected to supply approximately 360 million cylindrical battery shells from 2027 to 2031 [1] - Fuguang Co.'s major shareholder plans to reduce its stake by up to 3%, amounting to a maximum of 481.68 million shares [2] - Beixin Road and Bridge's consortium won a contract for a project worth 1.145 billion yuan, with two segments valued at 223.1 million yuan and 921.5 million yuan respectively [3] Group 2 - Jianyou Co.'s subsidiary received FDA approval for sodium selenite injection, aimed at providing selenium for parenteral nutrition in adults and pediatric patients [4] - China Galaxy received approval to publicly issue subordinated bonds totaling up to 20 billion yuan [6] - Changjiang Electric Power announced a cash dividend of 0.21 yuan per share, totaling 5.138 billion yuan [7] Group 3 - Zhongjin Company received approval to publicly issue corporate bonds totaling up to 20 billion yuan [8] - Daon Co. received a decision from the State Administration for Market Regulation not to conduct further antitrust review on its acquisition of Ningbo Aisikai Synthetic Rubber Co. [10] - Palm Co. won a project worth approximately 228 million yuan, which is expected to account for 7.44% of its audited revenue for 2024 [11] Group 4 - Kang En Bei's subsidiary received approval for clinical trials of TFA003 tablets for diabetic nephropathy [13] - Xinmai Medical's subsidiary obtained a medical device registration certificate for polyvinyl alcohol embolization microspheres [14] - Guangsheng Tang's innovative hepatitis B drug completed the enrollment of 578 participants in its Phase III clinical trial [15] Group 5 - Pianzaihuang's controlling shareholder received a loan commitment for up to 450 million yuan to support share buybacks [16] - Liya De plans to invest up to 100 million yuan in an industry fund focused on commercial aerospace [17] - Zhongwen Online plans to collaborate with Tencent on animation micro-short drama licensing, with an expected cooperation amount of 23.2 million yuan [19] Group 6 - Yungsheng Technology is planning to acquire control of Fengrui Fluorine Industry, with its stock continuing to be suspended [22] - Yinbang Co. received a sales order from HOLTEC ASIA for approximately 280 million yuan, expected to positively impact its operations in 2026 and 2027 [23] - Pailin Bio's subsidiary received a drug registration acceptance notice for human coagulation factor IX [24] Group 7 - Dao Dao Quan plans to apply for soybean oil delivery warehouse qualifications from the Dalian Commodity Exchange [25] - Qizheng Tibetan Medicine's subsidiary received a registration certificate for a traditional Chinese medicine product in Macau [26] - Vili Medical received EU MDR certification for multiple products [27][28] Group 8 - CITIC Bank plans to increase its investment in its wholly-owned subsidiary by 2 billion yuan [29] - Hayao Co. received approval for the consistency evaluation of its injectable drugs [30] - Zhifei Biological's freeze-dried varicella vaccine clinical trial received approval [31] Group 9 - Huibo Pu signed a contract worth 225 million USD for the Naft Khana oilfield recovery project [32] - Zhonggu Logistics plans to invest in the construction of two 6000 TEU container ships, with a total contract amount not exceeding 1.16 billion yuan [33] - Chongqing Beer reported a 10.43% increase in net profit for 2025, with revenue of 14.722 billion yuan [34] Group 10 - Huanxu Electronics reported a 12.16% increase in net profit for 2025, with revenue of 59.195 billion yuan [35] - Chengzhi Co.'s subsidiary successfully completed trial production of a high molecular weight polyethylene project [36] - Guangyang Co. signed a strategic cooperation agreement with Shenzhen Xuanchuang and Huangshan Guangyang [37]